BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million

Stock News

01/27

According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.

BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1123106870"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123106870\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123106870?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123106870","market":"us","top_or_hot":-1,"title":"BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 08:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1794554557.SGD","symbol_name":"Allianz All China Equity AT Acc H2-SGD","start_time":0,"source_url":"","article_id":"1123106870","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123106870","pubTimestamp":1769475381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","600030":"中信证券","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1564":"中资券商股","BK0028":"国家队","BK0276":"资本市场","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK1161":"生物科技","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK1516":"腾讯概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1147":"投资银行业与经纪业","BK0196":"行业龙头","06955":"博安生物","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","BK1521":"挪威政府全球养老基金持仓","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","06030":"中信证券","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"博安生物(06955)股东从中国证券登记结算香港转让股份至中信证券经纪香港，组合价值3.46亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"600030":1,"06955":1,"06030":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.\nBOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}